“DPP-IV inhibitors are widely used, well-tolerated antidiabetic agents that offer several advantages in clinical settings, especially for medically fragile populations, owing to their favorable efficacy and safety profile,” the researchers told Endocrine Today. “However, there is a concern that DPP-IV inhibitors may adversely impact the exocrine pancreas, owing to their pleiotropic effects. Read more . . .